SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Starfighters Space Inc

Starfighters Space Inc. (FJET) is trending with significant momentum following its recent IPO, fueled by high community interest in its low float and position within the burgeoning space sector. Traders are actively celebrating rapid gains and discussing potential for a short squeeze, despite some skepticism surrounding the company's current revenue. The unique aspect of FJET utilizing F-104 Starfighters for payload launches is a key talking point, adding to the speculative buying amidst broader excitement for space-related equities.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent drill results revealing exceptionally high-grade silver, which is fueling community excitement about its significant resource potential amid surging precious metals prices. The stock's dramatic uptick also sparks widespread discussion regarding prior corporate divestment and prominent investor accumulation, leading to strong speculation about a potential short squeeze and substantial long-term value.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending due to recent analyst upgrades from Jefferies and Wedbush, highlighting its growing commercial traction in quantum annealing and a dual roadmap. The community is actively debating whether these are legitimate catalysts or orchestrated pumps, especially with the company preparing to showcase practical quantum applications at CES 2026. This discussion reflects broader market sentiment regarding the future and valuation of the nascent quantum computing sector.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending due to strong community anticipation surrounding its imminent merger with Infleqtion, a quantum technology firm gaining significant attention. Investors are actively discussing Infleqtion's validated quantum sensing solutions for national security and defense, drawing comparisons to early Palantir, and highlighting its real revenue and strategic partnerships with entities like NVIDIA as key differentiators in the burgeoning quantum computing and AI landscape.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is surging following news of a significant $816 million prime contract from the U.S. Space Development Agency for missile-tracking satellites, capping a year of record-breaking Electron launches with 100% mission success. The community is highly bullish, viewing this as a transformative move solidifying RKLB's role as a vertically integrated space and defense prime contractor, with widespread anticipation of continued sector growth fueled by a potential SpaceX IPO.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

ABVX is experiencing a significant surge, driven by intensified speculation surrounding a potential acquisition, with Eli Lilly widely discussed as a suitor following reports of meetings with French officials. The community is actively debating substantial buyout premiums, captivated by the positive Phase 3 results for obefazimod in ulcerative colitis and its perceived "mega-blockbuster" potential in the inflammatory bowel disease market. This robust M&A interest further amplifies the stock's dramatic climb following its impressive clinical data, positioning ABVX as a prominent target in the active biotech sector.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is trending after a significant post-earnings sell-off, driven by investor concerns over declining gross margins, soft guidance, and persistent weakness in the crucial Greater China market. The community is sharply divided, with many seeing the drastic drop as an oversold dip-buying opportunity for a long-term turnaround, while others remain bearish on valuation, management, and the ongoing impact of tariffs and competition. Discussions also point to year-end tax loss harvesting contributing to the current selling pressure.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following news of its planned all-stock merger with fusion energy company TAE Technologies, valued at over $6 billion, coupled with recent strategic Bitcoin purchases. The community is actively debating the stock's future, with many anticipating a significant short squeeze and long-term energy potential, while others express skepticism over the company's unprofitability and the highly speculative nature of commercial fusion power.

Angel Studios, Inc. is a values-based distribution company for stories that amplify light to mainstream audiences. The company is headquartered in Provo, UT.

Angel Studios Inc. - Ordinary Shares - Class A

Angel Studios Inc

Angel Studios (ANGX) is trending amidst high anticipation for its upcoming animated film "David" and strong growth in its unique "Angel Guild" subscriber base, supported by recent analyst "Buy" ratings. The community is largely divided, with many bullish on its long-term potential as a values-driven entertainment alternative, while others debate recent share price volatility, short selling, and speculative ties to Elon Musk.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending amid strong bullish sentiment, fueled by its critical role in supplying the surging 'AI energy' demand for data centers and a series of positive analyst upgrades. The company's strategic position as a leading U.S. solar manufacturer, highlighted by its indirect link to Google's clean energy expansion through a key customer, underpins community discussions about its significant growth potential. Investors are actively discussing First Solar's leadership within the renewable energy sector as it addresses increasing power demands and benefits from domestic manufacturing policies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Equity

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

HEPA
Hepion Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HEPA News

HEPAHepion Pharmaceuticals Inc